Dawn Rachelle Wilson, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 436 S Mustang Rd, Yukon, OK 73099 Phone: 405-265-2733 Fax: 405-265-2926 |
Joseph Caleb Mitro, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1205 Health Center Pkwy Ste 240, Yukon, OK 73099 Phone: 405-717-5496 Fax: 405-717-5499 |
Kathryn Lee Jones, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1205 Health Center Pkwy, Suite 240b, Yukon, OK 73099 Phone: 405-717-5496 Fax: 405-717-5320 |
Dr. Elise Marie Schrop, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1205 Health Center Pkwy, Suite 240b, Yukon, OK 73099 Phone: 405-717-5496 Fax: 405-717-5320 |
Dr. Gregory Phillip Root, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1205 Health Center Pkwy Ste 240, Yukon, OK 73099 Phone: 405-717-5496 Fax: 405-717-5499 |
News Archive
Researchers from the University of Sydney, Australia determined that patients with a sedentary lifestyle who engage in routine physical activities lower their risk of nonalcoholic fatty liver disease (NAFLD).
A group of experts working under the umbrella of the International Parkinson and Movement Disorder Society, have developed a new tool for healthcare professionals that they hope will mark a significant advancement in the diagnosis and treatment of Parkinson's disease, especially in its early stages.
Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.
Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity.
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today.
› Verified 4 days ago